GENFIT to Present Latest ACLF Research at EASL Congress™ 2024

GENFIT, a late-stage biopharmaceutical company focused on rare liver diseases, will present its latest research on Acute on-Chronic Liver Failure (ACLF) at the EASL Congress™ 2024. A key event will be co-hosted with the European Foundation for the Study of Chronic Liver Failure (EF CLIF) to kick off a research collaboration.

Experts including Professor Richard Moreau from EF CLIF, Pascal Prigent, CEO of GENFIT, and Dean Hum, GENFIT's Chief Scientific Officer, will be speaking. EF CLIF and GENFIT will work with the Global Liver Institute and European Liver Patients' Association in this initiative.

GENFIT's presence at the Congress will feature two significant posters. The first suggests that GENFIT’s VS-01 captures metabolites associated with ACLF, while the second shows Nitazoxanide’s potential to protect against stress-induced cell death in preclinical models of ACLF.

Additional activities include the UNVEIL-IT® Investigator Meeting and an ELPA educational training event, emphasizing GENFIT’s commitment to patient advocacy and ongoing research in ACLF.